Stockreport

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCL...

IDEAYA Biosciences, Inc.  (IDYA) 
Last ideaya biosciences, inc. earnings: 3/24 06:00 am Check Earnings Report
PDF enhances the efficacy and durability of TOP1 ADCs in multiple preclinical models IDE849 Phase 1 study advancing globally to determine RP2D, including current dose eval [Read more]